0000000000424473

AUTHOR

Cristiana Bergamini

showing 2 related works from this author

Assessing Preferences in Patients with Head and Neck Squamous Cell Carcinoma: Phase I and II of Questionnaire Development.

2020

Shared-decision making for head and neck squamous cell carcinoma (HNSCC) is challenged by the difficulty to integrate the patient perception of value within the framework of a multidisciplinary team approach. The aim of this study was to develop a questionnaire to assess the preferences of HNSCC patients with respect to the disease trajectory, expected treatment, and toxicities. In accordance with the standardized EORTC Quality of Life Group&rsquo

Cancer Researchmedicine.medical_specialtyScoring criteriaDiseaselcsh:RC254-282Article03 medical and health sciences0302 clinical medicineQuality of lifehead and neck cancer; multimodal therapies; patient preferences; patient priorities; quality of lifeHealth caremedicineIn patient030212 general & internal medicinemultimodal therapiesneoplasmsbusiness.industryHead and neck cancermedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensHead and neck squamous-cell carcinoma3. Good healthstomatognathic diseasesPatient perceptionsOncologypatient prioritiesquality of life030220 oncology & carcinogenesisFamily medicinehead and neck cancerbusinesspatient preferences
researchProduct

Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: Activity and quality of life

2019

The treatment of patients with recurrent and/or metastatic (R/M) salivary gland adenoid cystic carcinoma (ACC) remains an unmet need.Patients with R/M disease with a history of clinical or symptomatic disease progression within 6 months and a maximum of 1 previous line of chemotherapy or a multiple kinase inhibitor received oral lenvatinib at a dose of 24 mg/day. The primary endpoint was the objective response rate; secondary endpoints included quality of life (QOL) (according to the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 Items [EORTC QLQ-C30] and the European Organization for Research and Treatment of Cancer Quality of Life Question…

AdultMaleadenoid cystic carcinoma; lenvatinib; quality of life; toxicityCancer Researchmedicine.medical_specialtyAdenoid cystic carcinomaAntineoplastic Agentslenvatinib03 medical and health scienceschemistry.chemical_compound0302 clinical medicineSwallowingQuality of lifeInternal medicinemedicineClinical endpointHumansadenoid cystic carcinomaProspective Studies030212 general & internal medicineNeoplasm MetastasisProtein Kinase InhibitorsDose-Response Relationship Drugbusiness.industryPhenylurea CompoundstoxicityCancerCommon Terminology Criteria for Adverse EventsMiddle AgedSalivary Gland Neoplasmsmedicine.diseaseCarcinoma Adenoid CysticSurvival AnalysisSalivary Gland Adenoid Cystic Carcinomaquality of lifeOncologychemistry030220 oncology & carcinogenesisQuinolinesFemaleNeoplasm Recurrence LocalbusinessLenvatinibCancer
researchProduct